Search results
Showing 871 to 885 of 2581 results for methods
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
NICE has developed a medtech innovation briefing (MIB) on Neon EEG electrode for EEG monitoring in newborns .
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446
In development Reference number: GID-TA11552 Expected publication date: 09 September 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406
In development Reference number: GID-TA11341 Expected publication date: 02 December 2026
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.
Identification and monitoring:- What are the most effective and cost-effective methods of increasing uptake of type 2 diabetes risk...
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
The principles that guide the development of NICE guidance and standards.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.
View recommendations for TA199Show all sections
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Awaiting development Reference number: GID-TA10879 Expected publication date: 11 November 2026